ALX Oncology Holdings (ALXO)
(Delayed Data from NSDQ)
$8.05 USD
-0.39 (-4.62%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $8.03 -0.02 (-0.25%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
ALXO 8.05 -0.39(-4.62%)
Will ALXO be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ALXO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALXO
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro
Shattuck (STTK) Announces Positive Interim Data on Cancer Drug
ALXO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regeneron (REGN), SNY Win FDA Nod for Kevzara Label Expansion
Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study
Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up
Other News for ALXO
Buy Rating Affirmed for ALX Oncology Amid Promising Evorpacept Combination Therapy Results
Buy Rating Affirmed for ALX Oncology Holdings on Strong Clinical Data and Solid Financial Valuation
Wall Street Analysts Are Bullish on Top Healthcare Picks
ALX Oncology Holdings (ALXO) Receives a Buy from Piper Sandler
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer